menu

Understanding the Fine Print: The Who, When, And What To Do About ARIA in Patients with Alzheimer’s Disease

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Understanding the Fine Print: The Who, When, And What To Do About ARIA in Patients with Alzheimer’s Disease - Closing Module

0.50 credits
30 minutes
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.50 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    Recently, Alzheimer’s Disease (AD) saw its first approvals for disease modifying therapy (DMT). With amyloid-beta (Aβ) targeting DMT now a reality, the entire way this condition is viewed and managed is changing. In particular, amyloid-related imaging abnormalities (ARIA), the most common adverse effects seen in DMT trials, are unique to this agent class, raising new questions and considerations across multiple medical specialties. As there is limited formal guidance on how to recognize and mange ARIA, this activity series employs experts in the fields of neurology, radiology, emergency medicine, and primary care to provide insight into how their fields are evolving to accommodate ARIA and to outline individual roles and best practices across specialties. This activity is part of a series of six distinct programs designed to introduce ARIA, detail its recognition and management in specific clinical settings, and ultimately optimize collaborative care.

    This activity finishes out the series by first providing an abbreviated outline of what has been addressed across activities 1-5 followed by a multidisciplinary discussion of questions and considerations that may impact the team-based execution of discussed strategies.  

  • Disclosure of Conflicts of Interest

    Medical Education Resources (MER) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All relevant financial relationships have been mitigated by MER. MER is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

    Planners' and Managers' Disclosure
    Efficient LLC and Medical Education Resources' planners and managers have no financial relationships to disclose.

    Faculty Disclosure
    DR. GALVIN REPORTED THE FOLLOWING FINANCIAL RELATIONSHIPS:
    CONSULTING FEES: Alpha Cognition, Biogen, Cognivue, Eisai, Eli Lilly, Genentech/Roche, Otsuka

    DR. CHIANG HAS NO REPORTED FINANCIAL RELATIONSHIPS.

     

    DR. CARPENTER HAS NO REPORTED FINANCIAL RELATIONSHIPS.

     

    DR. VEGA HAS NO REPORTED FINANCIAL RELATIONSHIPS.

  • Target Audience

    This activity is intended for neurodegenerative disease specialists, general neurologists, primary care physicians, radiologists, neuroradiologists, emergency medicine physicians, nurse practitioners, physician assistants, and other healthcare professionals involved in the diagnosis and long-term management of patients with early-stage AD neurobiology (mild cognitive impairment [MCI], early-AD).

  • Learning Objectives

    • Recognize key considerations that may impact a care team’s ability to successfully monitor for, identify, and/or treat ARIA and employ corresponding solutions to maximize interdisciplinary communication and patient outcomes
    • Understand what and how to communicate to patients, families, and other healthcare professionals regarding the risk and presence of ARIA to ensure safe, comprehensive, and consistent care in patients prescribed amyloid targeting DMT
  • Accreditation and Credit Designation Statements

    In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER) and Efficient LLC. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    PHYSICIAN CREDIT
    Medical Education Resources designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    PHYSICIAN ASSISTANTS (PAs) CREDIT

    Medical Education Resources has been authorized by the American Academy of Physician Assistants (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria.  This activity is designated for 0.5 AAPA Category 1 CME Credits.  Physician Assistants should only claim credit commensurate with the extent of their participation.

    CERTIFICATE OF PARTICIPATION FOR OTHER HEALTHCARE PROFESSIONALS
    A Certificate of Participation will be given upon completion of the enduring activity enabling participants to register their credit with the appropriate licensing boards or associations.

  • Disclaimer

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, Efficient LLC, and/or Lilly. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

  • Provider(s)/Educational Partner(s)

     

    This activity is jointly provided by Medical Education Resources (MER) and Efficient LLC.

  • Commercial Support

    This activity is supported by an educational grant from Lilly. 

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Recently, Alzheimer’s Disease (AD) saw its first approvals for disease modifying therapy (DMT). With amyloid-beta (Aβ) targeting DMT now a reality, the entire way this condition is viewed and managed is changing. In particular, amyloid-related imaging abnormalities (ARIA), the most common adverse effects seen in DMT trials, are unique to this agent class, raising new questions and considerations across multiple medical specialties. As there is limited formal guidance on how to recognize and mange ARIA, this activity series employs experts in the fields of neurology, radiology, emergency medicine, and primary care to provide insight into how their fields are evolving to accommodate ARIA and to outline individual roles and best practices across specialties. This activity is part of a series of six distinct programs designed to introduce ARIA, detail its recognition and management in specific clinical settings, and ultimately optimize collaborative care.

    This activity finishes out the series by first providing an abbreviated outline of what has been addressed across activities 1-5 followed by a multidisciplinary discussion of questions and considerations that may impact the team-based execution of discussed strategies.  

  • Disclosure of Conflicts of Interest

    Medical Education Resources (MER) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All relevant financial relationships have been mitigated by MER. MER is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

    Planners' and Managers' Disclosure
    Efficient LLC and Medical Education Resources' planners and managers have no financial relationships to disclose.

    Faculty Disclosure
    DR. GALVIN REPORTED THE FOLLOWING FINANCIAL RELATIONSHIPS:
    CONSULTING FEES: Alpha Cognition, Biogen, Cognivue, Eisai, Eli Lilly, Genentech/Roche, Otsuka

    DR. CHIANG HAS NO REPORTED FINANCIAL RELATIONSHIPS.

     

    DR. CARPENTER HAS NO REPORTED FINANCIAL RELATIONSHIPS.

     

    DR. VEGA HAS NO REPORTED FINANCIAL RELATIONSHIPS.

  • Target Audience

    This activity is intended for neurodegenerative disease specialists, general neurologists, primary care physicians, radiologists, neuroradiologists, emergency medicine physicians, nurse practitioners, physician assistants, and other healthcare professionals involved in the diagnosis and long-term management of patients with early-stage AD neurobiology (mild cognitive impairment [MCI], early-AD).

  • Learning Objectives

    • Recognize key considerations that may impact a care team’s ability to successfully monitor for, identify, and/or treat ARIA and employ corresponding solutions to maximize interdisciplinary communication and patient outcomes
    • Understand what and how to communicate to patients, families, and other healthcare professionals regarding the risk and presence of ARIA to ensure safe, comprehensive, and consistent care in patients prescribed amyloid targeting DMT
  • Accreditation and Credit Designation Statements

    In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER) and Efficient LLC. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    PHYSICIAN CREDIT
    Medical Education Resources designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    PHYSICIAN ASSISTANTS (PAs) CREDIT

    Medical Education Resources has been authorized by the American Academy of Physician Assistants (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria.  This activity is designated for 0.5 AAPA Category 1 CME Credits.  Physician Assistants should only claim credit commensurate with the extent of their participation.

    CERTIFICATE OF PARTICIPATION FOR OTHER HEALTHCARE PROFESSIONALS
    A Certificate of Participation will be given upon completion of the enduring activity enabling participants to register their credit with the appropriate licensing boards or associations.

  • Disclaimer

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, Efficient LLC, and/or Lilly. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

  • Provider(s)/Educational Partner(s)

     

    This activity is jointly provided by Medical Education Resources (MER) and Efficient LLC.

  • Commercial Support

    This activity is supported by an educational grant from Lilly. 

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule1 Mar 2024